Sperzel John J III 4
4 · T2 Biosystems, Inc. · Filed Mar 9, 2023
Insider Transaction Report
Form 4
Sperzel John J III
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-02-24+6,667→ 20,227 total - Sale
Common Stock
2023-02-28$0.59/sh−2,898$1,710→ 17,329 total - Exercise/Conversion
Common Stock
2023-02-20+16,000→ 20,435 total - Sale
Common Stock
2023-02-22$0.65/sh−6,875$4,469→ 13,560 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−16,000→ 32,000 total→ Common Stock (16,000 underlying) - Exercise/Conversion
Restricted Stock Units
2023-02-20−6,667→ 6,667 total→ Common Stock (6,667 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on May 20, 2021.
- [F3]On February 20, 2022 the reporting person was granted 48,000 RSU's that vest in three equal annual installments commencing on February 20, 2023
- [F4]On February 24, 2021 the reporting person was granted 20,000 RSU's that vest in three equal annual installments commencing on February 24, 2022.